Eculizumab biosimilar - EPIRUS Biopharmaceuticals

Drug Profile

Eculizumab biosimilar - EPIRUS Biopharmaceuticals

Alternative Names: BOW 080

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator Bioceros
  • Developer EPIRUS Biopharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 16 Nov 2015 Early research in Haemolytic uraemic syndrome in USA (unspecified route)
  • 16 Nov 2015 Early research in Paroxysmal nocturnal haemoglobinuria in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top